Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14699396 | 0.85 | CYP1A2 (0.37) | KCNA5KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14699398 | 0.85 | CYP1A2 (0.37) | KCNA5KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21484195 | 0.84 | KCNA5 (0.46) | KCNA5KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL24036698 | 0.83 | KCNA5 (0.37) | KCNA5KDM4ECYP1A2HTTRAB9A | |
| SCHEMBL25623852 | 0.83 | KCNA5 (0.37) | KCNA5KDM4ECYP1A2HTTRAB9A | |
| SCHEMBL6381109 | 0.81 | CASP3 (0.48) | KDM4ECASP3HTTRAB9APOLB | |
| SCHEMBL15956030 | 0.81 | CASP3 (0.48) | KDM4ECASP3HTTRAB9APOLB | |
| SCHEMBL18833917 | 0.81 | KCNA5 (0.42) | KCNA5KDM4ECYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL7976149 | 0.80 | CASP3 (0.47) | KDM4ECASP3HTTRAB9APOLB | |
| SCHEMBL21480487 | 0.79 | CTSA (0.40) | KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12221416-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3773573-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | Morphic Therapeutic, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112312910-A | Human integrin alpha 4 beta 7 antagonists | 莫菲克医疗股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| CN-103906743-A | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA | 2014-07-02 | — | — | CN | disclosed |
| EP-2744802-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | Piramal Imaging SA (CH) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013023795-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013023795-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2013-02-21 | — | — | WO | disclosed |
| EP-1988078-B1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | ORTHO MCNEIL PHARM INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1988078-A1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | Ortho-McNeil Pharmaceutical, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1184374-A1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6069254-A | Carboxamide derivatives of piperidine for the treatment of thrombosis disorders | ORTHO PHARMACEUTICAL CORP. (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0923555-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997041102-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221416-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | KCNA5 1297/4885KDM4E 2147/4885CYP1A2 4498/4885 |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | KCNA5 1144/4885KDM4E 2056/4885CYP1A2 4261/4885 |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | KCNA5 1144/4885KDM4E 2056/4885CYP1A2 4261/4885 |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | KCNA5 1042/4885KDM4E 2404/4885CYP1A2 4579/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | KCNA5 1144/4885KDM4E 2056/4885CYP1A2 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.